US FDA inspection at Auro Peptides completed with single observation

Regulatory & Legal View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹1621.30

prior close

₹1613.60

announcement price

After-mkt

timing

Nifty Midcap 150market+0.1%-0.8% vs market

Pharmaceuticals peers, median of 176sector-0.2%-0.5% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.3

15m

+0.2

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7+0.1-0.8-0.2-0.5

Next day

-0.2+0.5-0.7-0.5+0.3

-0.0+0.5-0.6-0.1+0.0

+0.1+0.4-0.3-0.0+0.1

+1.9+0.4+1.5+0.5+1.4

+5.9+0.6+5.4+0.5+5.4

+3.3-1.3+4.6+0.7+2.6

15d

+2.4-4.5+6.9+0.2+2.1

+6.1-4.0+10.1+2.0+4.0

-1.9-11.1+9.2-6.7+4.7

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 176Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA conducted a routine inspection at Auro Peptides Ltd, Aurobindo Pharma's subsidiary that makes Peptide APIs in Telangana, from August 17 to 21, 2026. The inspection ended with only one observation related to facility and equipment maintenance, with no data integrity or GMP compliance issues. Corrective action was already started during the inspection, and a formal response will be sent within the required timeline.

Likely market impact

Positive. A single minor observation with no data integrity or GMP concerns reaffirms manufacturing compliance at the subsidiary.